

Brandes Investment Partners
International Equity Strategy Notes
Second Quarter 2025 (1 April – 30 June 2025)

The Brandes International Equity Strategy rose 10.79% (gross of fees), underperforming its benchmark, the MSCI EAFE Index, which was up 11.78% in the quarter, and outperforming the MSCI EAFE Value Index, which returned 10.11%.

Contributors to Performance

The largest contributors to performance reflected a combination of stock selection in technology and materials, as well as continued recovery in select U.K. consumer names.

Among the top contributors was STMicroelectronics, which benefited from stronger-than-expected sales to its industrial end-market and an anticipated recovery in its automotive end-market. Taiwan Semiconductor Manufacturing Company (TSMC) also helped returns as its leadership in advanced chip manufacturing and central role in AI-related demand drove positive investor sentiment and earnings momentum.

Within materials, shares of Mexico-based Cemex and Germany's Heidelberg Materials increased after both companies reported improved earnings results. In the U.K., J Sainsbury and Tesco appreciated significantly, thanks to resilient consumer demand, improved pricing power, and continued progress on cost efficiency initiatives.

Other standout performers included South Korean Hana Financial Group, which rose materially as Korean banks broadly benefited from rising net interest margins and improving credit quality. Hana's capital discipline and earnings growth further boosted market sentiment.

Detractors from Performance

Our overweights to health care and energy, two of the weakest-performing sectors in the benchmark, detracted from relative returns. Additionally, several of our holdings in both sectors declined.

France-based TotalEnergies and Brazil's Petrobras hurt performance as oil prices declined amid tariff concerns and geopolitical conflicts. Within health care, notable detractors included pharmaceutical holdings Sanofi and Takeda Pharmaceutical. Sanofi declined due to market worries about its profit margins, a concern we consider short-term in nature. We believe Sanofi remains well positioned for steady top-line growth, supported by its flagship drug Dupixent, its improved research and development productivity, and a lack of major patent expirations for the next five years. We continue to view Sanofi as a stable cash-flow generator with upside optionality from its pipeline.

After a strong rebound in the first quarter, Alibaba declined amid macroeconomic uncertainty in China. We remain confident in the company's long-term positioning in e-commerce and cloud computing, and believe the shares continue to trade at an attractive valuation level.

Other detractors included Hong Kong-based Budweiser Brewing APAC, Japanese machinery firm Kubota, Singapore-headquartered agribusiness group Wilmar International, and Swiss watchmaker Swatch.

Budweiser faced volume pressures in China and Southeast Asia, while Kubota was affected by weaker-than-expected demand in its construction equipment segment. Similarly, both Wilmar and Swatch experienced margin compression amid subdued consumer sentiment across Asia. Despite the headwinds, we believe these positions warrant continued inclusion in the portfolio given their long-term earnings potential and compelling valuations.

Portfolio Activity

There were no new buys during the quarter. However, we divested three positions: U.K. aerospace and defense firm Rolls-Royce Holdings, South Korean tobacco company KT&G, and France-based food products business Danone.

The exit from Rolls-Royce marked the conclusion of an investment that began in May 2022. At the time of purchase, the company was trading at a significant discount to our estimate of intrinsic value, following a period of severe disruption caused by the COVID-19 pandemic. Our thesis centered on Rolls-Royce's dominant position in the widebody

aircraft engine market, its high-margin aftermarket services business, and its exposure to long-term secular growth in global air travel.

Over the course of our holding period, we made several upward adjustments to our estimate of Rolls-Royce's intrinsic value as the company made substantial progress in strengthening its balance sheet, improving operational execution, and restoring profitability. By mid-2025, the stock had appreciated significantly, supported by a rebound in civil aerospace volumes, margin expansion, and a return to investment-grade credit metrics. With the stock trading up to our revised intrinsic value estimate, we exited the position during the quarter. While we continue to view Rolls-Royce as a high-quality industrial franchise, we believe the risk/reward profile has become less compelling compared to other opportunities in the portfolio.

Similarly, KT&G and Danone approached our estimates of intrinsic value following periods of strong performance, leading us to exit the positions. We redeployed the capital to add to several positions, including some of our recent purchases from the past year, such as France-based tech services provider Capgemini and beverage firm Pernod Ricard.

Year-to-Date Briefing

The Brandes International Equity Strategy rose 22.18%, outperforming its benchmark, the MSCI EAFE Index, which appreciated 19.45% in the six months ended 30 June 2025, and slightly underperforming the MSCI EAFE Value Index, which rose 22.84%.

Although the outperformance of value stocks (MSCI EAFE Value vs. MSCI EAFE) has been a tailwind for the strategy given our value exposure, it was our stock selection across multiple sectors that mostly drove our outperformance relative to the benchmark. Leading contributors included holdings in consumer discretionary, led by Alibaba, and in materials, most notably Heidelberg Materials. The strategy also benefited from holdings in technology and health care. Other standout contributors included aerospace and defense companies Embraer and Rolls-Royce, as well as France-based holdings BNP Paribas and Orange. These names reflect strength in both emerging markets and European industrials, with common themes including balance sheet improvement, capital returns, and exposure to infrastructure and digital transformation.

Meanwhile, our underweights to financials and European defense companies hurt relative returns. At the holding level, notable detractors included luxury goods companies Kering and Swatch, as well as advertising agency WPP. Other detractors were concentrated in consumer discretionary (e.g., Henkel) and health care (e.g., Sanofi, Astellas Pharma), where macro uncertainty and margin pressure weighed on sentiment.

Current Positioning

As of 30 June, the portfolio's largest overweights are in consumer staples and health care. Additionally, after having a roughly equal weight to technology at the beginning of the year, we now have an overweight in the sector. Meanwhile, the portfolio's most significant underweights are in financials and industrials.

Geographically, we continue to have a larger allocation to businesses in Europe and select emerging markets, particularly Mexico, South Korea, and Brazil. We believe the differences between the Brandes International Equity Strategy and the MSCI EAFE Index make it an excellent complement and diversifier to passive and growth-oriented strategies.

The significant appreciation and outperformance of international (MSCI EAFE vs. MSCI USA) and value stocks (MSCI EAFE Value vs. MSCI EAFE) this year serves as a great reminder of the benefit of diversification. International and value stocks underperformed for much of the decade prior to the COVID-19 pandemic, likely resulting in many investors being under-allocated to international value stocks. As a result, international value stocks traded near some of the largest discounts in their history relative to growth stocks (MSCI EAFE Growth). Despite the strong rebound this year, international value stocks continue to trade within the least expensive quartile relative to growth (MSCI EAFE Value vs. MSCI EAFE Growth) since the inception of the style indices. This is evident across various valuation measures, including price/earnings, price/cash flow, and enterprise value/sales. Historically, such discount levels often signaled attractive subsequent relative returns for value stocks over the subsequent three- to five-year period. This is encouraging for us as our strategy, guided by our value philosophy and process, has had the tendency to outperform the value index when it outperformed the benchmark.

The Brandes International Equity Strategy trades at more compelling valuation levels, in our opinion, while offering more attractive long-term growth characteristics relative to both the benchmark and the MSCI EAFE Value Index. We believe the strategy is well-positioned to benefit if there is a continued rotation toward value and international equities. Looking ahead, we remain optimistic about the prospects of our holdings.

For term definitions: <https://www.brandes.com/termdefinitions>

The MSCI EAFE Index with net dividends captures large and mid cap representation of developed market countries excluding the U.S. and Canada.

The MSCI EAFE Value Index with gross dividends captures large and mid cap securities across developed market countries, excluding the United States and Canada, exhibiting value style characteristics, defined using book value to price, 12-month forward earnings to price, and dividend yield.

The MSCI EAFE Growth Index with gross dividends captures large and mid cap securities across developed market countries, excluding the United States and Canada, exhibiting growth style characteristics, defined using long-term forward earnings per share (EPS) growth rate, short-term forward EPS growth rate, current internal growth rate, long-term historical EPS growth trend, and long-term historical sales per share growth trend.

The MSCI USA Index measure the performance of the large and mid cap segments of the U.S. equity market.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

Ireland/Europe: FOR PROFESSIONAL INVESTOR USE ONLY. Issued by Brandes Investment Partners (Europe) Limited (Brandes Europe), Alexandra House, The Sweepstakes, Ballsbridge, Dublin, D04 C7H2, Ireland. Registered in Ireland Number 510203. Authorised and regulated by the Central Bank of Ireland. This report is being provided for information purposes only, no representation or warranty is made, whether express or implied as to the accuracy or completeness of the information provided. To the fullest extent permitted by law Brandes Europe shall not be liable for any loss or damage suffered by any person as a result of the receipt of this report. Recipients of this report should obtain their own professional advice. The distribution of this report may be restricted by law. No action has been or will be taken by Brandes Europe to permit the possession or distribution of this report in any jurisdiction where action for that purpose may be required. Accordingly, this report may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this report is communicated should inform themselves about and observe any such restrictions. This information is being issued only to, and/or is directed only at (i) persons who have professional experience in matters relating to investments or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This report is a confidential communication to, and solely for the use of, the persons to whom it is distributed to by Brandes Europe.